Skip to content

US · PYPD · BIOTECHNOLOGY

PolyPid Ltd. (PYPD) intrinsic value and stock valuation

$6.12as of 2026-11-21 · Mkt cap 49.32M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

PolyPid Ltd. DCF and intrinsic value

InvestorsCraft values PYPD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PYPD’s statements →

PolyPid Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Petah Tikva, HM 4959376 polypid.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-34.17M
20122025
Free cash flow
$0.00
20122025
Total equity
$11M-31.5% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-32.97M-$-28.03M-$-22.87M-$-38.89M-$-43.15M
Net income-$-34.17M-$-29.02M-$-23.86M-$-39.52M-$-40.71M
EPSd-$-2.09M-$-4.91M-$-17.04M-$-30.4M-$-32.57M
Operating cash flow$0.00-$-21.96M-$-17.24M-$-34.32M-$-32.39M
Capital expenditure$0.00-$-80K-$-200K-$-1.77M-$-2.99M
Free cash flow$0.00-$-22.04M-$-17.43M-$-36.08M-$-35.38M
Total assets$22.3M$25.2M$15.4M$26M$44.2M
Total debt$2.8M$9.62M$11.8M$13.7M$0.00
Net debt-$-3.61M-$-6.02M$6.17M$5.18M-$-9.82M
Total equity$11M$7.68M-$-2.1M$5.83M$36M
Cash and short-term investments$12.9M$15.6M$5.61M$12.6M$32.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$1.72M$1.12M
Gross profit$0.00$0.00$0.00-$-1.72M-$-1.12M
Research and development expenses$23.8M$22.8M$16.2M$28M$30.4M
Selling, general and administrative expenses$9.16M$5.22M$6.72M$10.9M$12.5M
Other expenses$0.00$0.00$0.00-$-1.72M-$-850K
Operating expenses$33M$28M$22.9M$37.2M$42M
Cost and expenses$33M$28M$22.9M$38.9M$43.2M
Interest income$0.00$440K$550K$270K$470K
Interest expense$690K$1.52M$1.71M$1.34M$0.00
Depreciation and amortization$1.62M$1.62M$1.82M$1.72M$1.12M
Ebitda-$-31.86M-$-25.83M-$-20.26M-$-36.37M-$-41.48M
Operating income-$-32.97M-$-28.03M-$-22.87M-$-38.89M-$-43.15M
Total other income/expenses, net-$-1.2M-$-950K-$-930K-$-540K$540K
Income before tax-$-34.16M-$-28.98M-$-23.8M-$-39.43M-$-42.6M
Income tax expense$10K$40K$70K$130K$0.00
Net income-$-34.17M-$-29.02M-$-23.86M-$-39.52M-$-40.71M
Weighted average shares outstanding$16.4M$5.91M$1.4M$1.3M$1.25M
Weighted average diluted shares outstanding$16.4M$5.91M$1.4M$1.3M$1.25M
Balance sheet
20252024202320222021
Cash and short-term investments$12.9M$15.6M$5.61M$12.6M$32.2M
Net receivables$0.00$0.00$0.00$300K$120K
Inventory$1.11M$0.00$0.00$0.00$0.00
Total current assets$15.2M$16.6M$6.07M$14.2M$34.8M
Property, plant and equipment, net$6.77M$8.37M$9.22M$11.7M$8.76M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$7.08M$8.65M$9.3M$11.8M$9.42M
Total assets$22.3M$25.2M$15.4M$26M$44.2M
Accounts payable$2.86M$2.41M$770K$1.14M$4.14M
Short-term debt$2.15M$7.71M$4.54M$4.98M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$270K
Total current liabilities$7.74M$12.7M$7.29M$8.55M$8.08M
Long-term debt$650K$1.91M$7.24M$8.75M$0.00
Deferred revenue, non-current$0.00$2.55M$2.55M$2.55M$0.00
Total non-current liabilities$3.6M$4.86M$10.2M$11.6M$200K
Capital lease obligations$1.81M$2.2M$1.4M$2.13M$0.00
Total liabilities$11.3M$17.5M$17.5M$20.1M$8.28M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-301.5M-$-267.33M-$-238.31M-$-214.44M-$-174.89M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$11M$7.68M-$-2.1M$5.83M$36M
Total investments$6.53M$0.00$0.00$4.04M$22.4M
Total debt$2.8M$9.62M$11.8M$13.7M$0.00
Net debt-$-3.61M-$-6.02M$6.17M$5.18M-$-9.82M
Cash flow statement
20252024202320222021
Net income-$-34.17M-$-29.02M-$-23.86M-$-39.56M-$-42.6M
Depreciation and amortization$0.00$1.62M$1.82M$1.72M$1.12M
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital$0.00$1.92M-$-110K-$-1.08M$4.35M
Accounts receivable$0.00$0.00$0.00$0.00$120K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$1.64M-$-370K-$-3.1M$2.22M
Net cash provided by operating activities$0.00-$-21.96M-$-17.24M-$-34.32M-$-32.39M
Investments in property, plant and equipment$0.00-$-80K-$-200K-$-1.77M-$-2.99M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-330K$3.8M$16.6M$36.9M
Common stock issued$0.00$35.9M$12.7M$5.12M$1.03M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$0.00$32.4M$9.98M$16.4M$1.03M
Net change in cash-$-9.21M$10.2M-$-3.45M-$-1.15M$5.51M
Cash at end of period$6.59M$15.8M$5.61M$9.06M$10.2M
Operating cash flow$0.00-$-21.96M-$-17.24M-$-34.32M-$-32.39M
Capital expenditure$0.00-$-80K-$-200K-$-1.77M-$-2.99M
Free cash flow$0.00-$-22.04M-$-17.43M-$-36.08M-$-35.38M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About PolyPid Ltd.

        PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.

        CEO
        Dikla Czaczkes Akselbrad
        Employees
        72
        Beta
        1.40

        Explore

        Frequently asked questions

        What is the intrinsic value of PolyPid Ltd. (PYPD)?

        InvestorsCraft does not currently publish an intrinsic value for PYPD. How the IC value is calculated.

        Is PYPD undervalued?

        InvestorsCraft does not publish an undervaluation signal for PYPD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.